Eisai announces 2008 C.A.R.E. recipient
WOODCLIFF LAKE, N.J. Tracey Pierce, a clinical pharmacist with Blanchard Valley Hospital in Findlay, Ohio, and associate professor of pharmacy at Ohio Northern University, is this year’s recipient of the C.A.R.E. Pharmacy Award, drug maker Eisai announced Monday.
Eisai co-sponsors the award with the Alzheimer’s Association. The award, whose name stands for Commitment to Alzheimer’s Recognition of Excellence, acknowledges pharmacists’ role in supporting Alzheimer’s patients and their families.
“As a member of the C.A.R.E. Pharmacy Award selection committee, I saw the impressive contributions of nominated pharmacists who’ve worked cohesively as part of a team of care providers for those with Alzheimer’s disease,” Alzheimer’s Association senior director of programs Peter Reed said in a statement. “We commend this year’s winner on her extraordinary efforts to build a relationship with those living with Alzheimer’s and their caregivers, helping to educate them about Alzheimer’s disease and enhancing the support they receive.”
NOCA recognizes PTCB’s Corrigan with Certification Industry Leadership Award
WASHINGTON Melissa Murer Corrigan, executive director and chief executive officer of the Pharmacy Technician Certification Board, has received the 2008 Certification Industry Leadership Award from the National Organization for Competency Assurance, PTCB announced Tuesday.
PTCB said the award recognized Murer Corrigan’s leadership in the field of certification and licensure. She has certified more than 320,000 pharmacy technicians as the founding executive of PTCB.
“This award is a tribute to the hard work and dedication of all my colleagues and partners involved in making PTCB a success since our founding in 1995,” Murer Corrigan said in a statement. “The certification of pharmacy technicians in the U.S. has advanced the patient safety of millions of Americans, and I am so proud of the PTCB team and all of our certified technicians.”
FDA warns Shionogi to end unsupported Cedax claims
ROCKVILLE, Md. The Food and Drug Administration released a warning letter to Shionogi and Co. Tuesday regarding its antibiotic Cedax.
The FDA said the company made inflated claims about Cedax (ceftibuten) and downplayed the health risks associated with it. Promotional materials sent to doctors claimed the drug had “excellent tolerability,” even though data did not support the claim.
The drug is approved for treating mild to moderate bacterial infections.